La Jolla Pharmaceutical Stock Return On Equity
LJPCDelisted Stock | USD 6.22 0.00 0.00% |
La Jolla Pharmaceutical fundamentals help investors to digest information that contributes to La Jolla's financial success or failures. It also enables traders to predict the movement of LJPC Stock. The fundamental analysis module provides a way to measure La Jolla's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to La Jolla stock.
LJPC |
La Jolla Pharmaceutical Company Return On Equity Analysis
La Jolla's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current La Jolla Return On Equity | 0.0544 |
Most of La Jolla's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, La Jolla Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, La Jolla Pharmaceutical has a Return On Equity of 0.0544. This is 100.23% lower than that of the Healthcare sector and 100.15% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 117.55% lower than that of the firm.
LJPC Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses La Jolla's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of La Jolla could also be used in its relative valuation, which is a method of valuing La Jolla by comparing valuation metrics of similar companies.La Jolla is currently under evaluation in return on equity category among related companies.
LJPC Fundamentals
Return On Equity | 0.0544 | |||
Return On Asset | 1.64 | |||
Profit Margin | 10.08 % | |||
Operating Margin | 4.68 % | |||
Current Valuation | 242.85 M | |||
Shares Outstanding | 27.52 M | |||
Shares Owned By Insiders | 1.91 % | |||
Shares Owned By Institutions | 71.79 % | |||
Number Of Shares Shorted | 202.51 K | |||
Price To Earning | 38.88 X | |||
Price To Book | 30.11 X | |||
Price To Sales | 3.29 X | |||
Revenue | 52.01 M | |||
Gross Profit | 63.08 M | |||
EBITDA | 4.09 M | |||
Net Income | 5.24 M | |||
Cash And Equivalents | 44.56 M | |||
Cash Per Share | 1.74 X | |||
Total Debt | 124.8 M | |||
Debt To Equity | 7.16 % | |||
Current Ratio | 3.92 X | |||
Book Value Per Share | (3.36) X | |||
Cash Flow From Operations | 13.59 M | |||
Short Ratio | 0.46 X | |||
Earnings Per Share | (1.44) X | |||
Price To Earnings To Growth | 11.72 X | |||
Number Of Employees | 61 | |||
Beta | 1.97 | |||
Market Capitalization | 171.2 M | |||
Total Asset | 89.52 M | |||
Retained Earnings | (1.06 B) | |||
Working Capital | 79.5 M | |||
Current Asset | 86.74 M | |||
Current Liabilities | 7.24 M | |||
Z Score | -14.8 |
About La Jolla Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze La Jolla Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of La Jolla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of La Jolla Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards La Jolla in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, La Jolla's short interest history, or implied volatility extrapolated from La Jolla options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in LJPC Stock
If you are still planning to invest in La Jolla Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the La Jolla's history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stocks Directory Find actively traded stocks across global markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |